Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [7921]

New insights into childhood brain cancer tumour growth and regression

New insights into childhood brain cancer tumour growth and regression

Breast cancer recruits bone marrow cells to increase cancer cell proliferation

Breast cancer recruits bone marrow cells to increase cancer cell proliferation

SABCS 2018: Black women have worse breast cancer outcomes despite receiving similar treatment as white women

SABCS 2018: Black women have worse breast cancer outcomes despite receiving similar treatment as white women

SABCS 2018: Low-dose tamoxifen was safe and effective at reducing recurrence and new breast disease for patients with DCIS, LCIS, and ADH

SABCS 2018: Low-dose tamoxifen was safe and effective at reducing recurrence and new breast disease for patients...

SABCS 2018: Phase III KATHERINE clinical trial crossed early reporting boundary and met its primary endpoint

SABCS 2018: Phase III KATHERINE clinical trial crossed early reporting boundary and met its primary endpoint

SABCS 2018: Adjuvant chemotherapy might not add benefit in breast cancer patients who have excellent response to neoadjuvant chemotherapy

SABCS 2018: Adjuvant chemotherapy might not add benefit in breast cancer patients who have excellent response to...

SABCS 2018: Adjuvant capecitabine did not significantly improve outcomes for patients with early-stage triple-negative breast cancer

SABCS 2018: Adjuvant capecitabine did not significantly improve outcomes for patients with early-stage triple...

More than 260 new drugs to treat cancer? Researchers look for "new cures in old drugs"

More than 260 new drugs to treat cancer? Researchers look for "new cures in old drugs"

ASH 2018: Ibrutinib-based therapy more effective, safer in younger patients with previously untreated CLL compared with current standard of care

ASH 2018: Ibrutinib-based therapy more effective, safer in younger patients with previously untreated CLL compared...

ASH 2018: Daratumumab increases progression-free survival in transplant-ineligible multiple myeloma

ASH 2018: Daratumumab increases progression-free survival in transplant-ineligible multiple myeloma

More from ecancer